Health 2.0 Europe 2011 - Registration is Now Open

27 - 28 October 2011, Berlin, Germany.
Health 2.0 Europe integrates the best of European web/mobile based technologies, and compares, contrasts and contextualizes them with leading examples of Health 2.0 from around the world. You will see what works in the context of Europe's evolving healthcare systems, and what the "boundary-less" online world means for consumers and physicians working in distinct healthcare systems - all in our lauded format of "rapid-fire" technology demos, provocative keynotes, and interactive discussions.

2011 themes will include:

  • Patient and physician social networks
  • Search & content
  • Communities and data production
  • Consumer and provider tools
  • Health promotion, behavior change and Wellness 2.0
  • Data utility layer & tools
  • System integration
  • Health 2.0 financing
  • Cloud computing and unplatforms

There'll also be a presentation of the latest thinking about Health 2.0 in the European context, special videos, and an unconference session.

A signature of the Health 2.0 conferences, Launch!, will be back by popular demand. Come witness live demos of debuting technologies that will shape the future of healthcare.

Registration to the 2nd annual Health 2.0 Europe Conference is now open. Prices increase on August 15th, so don't wait till it's too late: get your ticket today and save up to 400€.

For further information, please visit:
http://www.health2con.com/europe/

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...